Compounds and methods for inhibiting alpha-1 beta-1 integrins
CA 2421786 A1 · Owner: Marcinkiewicz, Cezary · Inventors: Marcinkiewicz, Cezary
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Obtustatin is a novel, RGD-independent short disintegrin that potently and selectively inhibits the binding of .alpha.1.beta.1 integrin to its adhesive ligand. Obtustatin, and fragments, derivatives homologs and analogs of , obtustatin may be used to treat diseases and modulate biological conditions associated with .alpha.1.beta.1 integrin.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 12, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 12, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 12, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.